Drug Trial Radar · NCT04045145
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 12, 2019
Primary completion
Jul 2, 2021
Study completion Jul 2, 2021
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Aug 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, multiple-dose, study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 (crinecerfont) in pediatric participants (14 to 17 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
Conditions
- CAH - Congenital Adrenal Hyperplasia
Interventions
CrinecerfontDrug
Crinecerfont administered orally for 14 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average)Time frame: Baseline, Day 14
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
Aurora, Colorado
Neurocrine Clinical Site
Ann Arbor, Michigan
Neurocrine Clinical Site
Minneapolis, Minnesota
Neurocrine Clinical Site
Philadelphia, Pennsylvania
Neurocrine Clinical Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.